BR112012004919A2 - potencializadores alostericos de mglur4, composição e metodos de tratamentos de disfunção neurologica - Google Patents
potencializadores alostericos de mglur4, composição e metodos de tratamentos de disfunção neurologicaInfo
- Publication number
- BR112012004919A2 BR112012004919A2 BR112012004919A BR112012004919A BR112012004919A2 BR 112012004919 A2 BR112012004919 A2 BR 112012004919A2 BR 112012004919 A BR112012004919 A BR 112012004919A BR 112012004919 A BR112012004919 A BR 112012004919A BR 112012004919 A2 BR112012004919 A2 BR 112012004919A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- treatment methods
- neurological dysfunction
- allosteric enhancers
- mglur4 allosteric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24003109P | 2009-09-04 | 2009-09-04 | |
PCT/US2010/048030 WO2011029104A1 (en) | 2009-09-04 | 2010-09-07 | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012004919A2 true BR112012004919A2 (pt) | 2019-09-24 |
Family
ID=43649686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012004919A BR112012004919A2 (pt) | 2009-09-04 | 2010-09-07 | potencializadores alostericos de mglur4, composição e metodos de tratamentos de disfunção neurologica |
Country Status (12)
Country | Link |
---|---|
US (1) | US8779157B2 (pt) |
EP (1) | EP2473055A4 (pt) |
JP (1) | JP2013503909A (pt) |
CN (1) | CN102740699A (pt) |
AU (1) | AU2010289281A1 (pt) |
BR (1) | BR112012004919A2 (pt) |
CA (1) | CA2773038A1 (pt) |
IL (1) | IL218426A0 (pt) |
IN (1) | IN2012DN02580A (pt) |
RU (1) | RU2012114770A (pt) |
SG (1) | SG178999A1 (pt) |
WO (1) | WO2011029104A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2751176A1 (en) | 2009-01-28 | 2010-08-05 | Vanderbilt University | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
HUE034849T2 (en) * | 2013-09-25 | 2018-03-28 | Hoffmann La Roche | Ethinyl derivatives |
EP2853532B1 (en) | 2013-09-28 | 2020-12-09 | Instytut Farmakologii Polskiej Akademii Nauk | 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III |
TWI649310B (zh) * | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
CR20160384A (es) * | 2014-02-25 | 2016-11-07 | Hoffmann La Roche | Derivados de etilino |
US10221172B2 (en) | 2015-01-13 | 2019-03-05 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
WO2016123629A1 (en) | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
CN107207481B (zh) * | 2015-03-19 | 2020-03-03 | 豪夫迈·罗氏有限公司 | 作为mglur4的调节剂的3-(4-乙炔基苯基)六氢嘧啶-2,4-二酮衍生物 |
US9987242B2 (en) | 2015-05-05 | 2018-06-05 | Northwestern University | Treatment of Levodopa-induced Dyskinesias |
PE20180356A1 (es) | 2015-07-15 | 2018-02-21 | Hoffmann La Roche | Derivados de etinilo como moduladores del receptor metabotropico del glutamato |
CN109476671B (zh) | 2016-07-18 | 2021-09-24 | 豪夫迈·罗氏有限公司 | 乙炔基衍生物 |
US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US11242342B2 (en) | 2016-11-08 | 2022-02-08 | Vanderbilt University | Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
WO2018089546A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline ether compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
WO2019006157A1 (en) | 2017-06-28 | 2019-01-03 | Vanderbilt University | QUINOLINE PYRIDINE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIALIZERS, COMPOSITIONS, AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTIONS |
UA128084C2 (uk) | 2017-08-16 | 2024-04-03 | Вандербілт Юніверсіті | ІНДАЗОЛОВІ СПОЛУКИ ЯК АЛОСТЕРИЧНІ ПОТЕНЦІАТОРИ mGLuR4, КОМПОЗИЦІЇ І СПОСОБИ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ ДИСФУНКЦІЙ |
AU2019309448A1 (en) | 2018-07-26 | 2021-01-14 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK529378A (da) | 1978-01-09 | 1979-07-10 | Shell Int Research | Anilidderivater |
TW521073B (en) | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
FR2725206B1 (fr) | 1994-09-29 | 1996-12-06 | Roussel Uclaf | Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
USRE38132E1 (en) | 1997-03-03 | 2003-06-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Phenylpyrrolidines, phenylimidazolidines,3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease |
US6355664B1 (en) | 1997-03-03 | 2002-03-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease |
FR2764889B1 (fr) | 1997-06-20 | 2000-09-01 | Sod Conseils Rech Applic | Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
US6809088B2 (en) | 1997-03-24 | 2004-10-26 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
US6335445B1 (en) | 1997-03-24 | 2002-01-01 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
WO2000077519A1 (en) | 1999-06-15 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | Solid phase synthesis of n,n-disubstituted diazacycloalkylcarboxy derivatives |
WO2001007052A1 (en) | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
US6353013B1 (en) | 1999-07-21 | 2002-03-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
WO2001046195A1 (en) | 1999-12-21 | 2001-06-28 | Gpi Nil Holdings, Inc. | Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same |
EP1397137B1 (en) | 2001-05-25 | 2009-10-14 | Bristol-Myers Squibb Company | Hydantion derivatives as inhibitors of matrix metalloproteinases |
CA2462112A1 (en) | 2001-10-01 | 2003-04-10 | Bristol-Myers Squibb Company | Spiro-hydantoin compounds useful as anti-inflammatory agents |
US7030141B2 (en) * | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
AU2003259307A1 (en) | 2002-07-31 | 2004-02-16 | Euro-Celtique S.A. | Aryl substituted hydantoin compounds and their use as sodium channel blockers |
US7053112B2 (en) | 2002-09-24 | 2006-05-30 | Schering Aktiengesellschaft | Imidazolidinedione analogs useful as anticoagulants and antithrombotics |
AU2004255414A1 (en) | 2003-07-11 | 2005-01-20 | Boehringer Ingelheim Vetmedica Gmbh | Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor |
JP2007506741A (ja) * | 2003-09-23 | 2007-03-22 | メルク エンド カムパニー インコーポレーテッド | 向代謝性グルタミン酸受容体のピラゾール系調節剤 |
TWI345568B (en) * | 2004-04-02 | 2011-07-21 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same |
JP4810426B2 (ja) * | 2004-07-01 | 2011-11-09 | 第一三共株式会社 | Pde7阻害作用を有するチエノピラゾール誘導体 |
UY29896A1 (es) * | 2005-11-04 | 2007-06-29 | Astrazeneca Ab | Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
PE20090967A1 (es) | 2007-10-16 | 2009-08-10 | Novartis Ag | Derivados de imidazolidina 2,4-diona como moduladores del receptor npy y2 |
-
2010
- 2010-09-07 RU RU2012114770/13A patent/RU2012114770A/ru not_active Application Discontinuation
- 2010-09-07 CA CA2773038A patent/CA2773038A1/en not_active Abandoned
- 2010-09-07 US US13/394,309 patent/US8779157B2/en not_active Expired - Fee Related
- 2010-09-07 AU AU2010289281A patent/AU2010289281A1/en not_active Abandoned
- 2010-09-07 CN CN2010800490890A patent/CN102740699A/zh active Pending
- 2010-09-07 SG SG2012015525A patent/SG178999A1/en unknown
- 2010-09-07 WO PCT/US2010/048030 patent/WO2011029104A1/en active Application Filing
- 2010-09-07 JP JP2012528121A patent/JP2013503909A/ja not_active Withdrawn
- 2010-09-07 BR BR112012004919A patent/BR112012004919A2/pt not_active IP Right Cessation
- 2010-09-07 EP EP10814634A patent/EP2473055A4/en not_active Withdrawn
- 2010-09-07 IN IN2580DEN2012 patent/IN2012DN02580A/en unknown
-
2012
- 2012-03-01 IL IL218426A patent/IL218426A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2011029104A1 (en) | 2011-03-10 |
US20120245153A1 (en) | 2012-09-27 |
EP2473055A4 (en) | 2013-02-13 |
CA2773038A1 (en) | 2011-03-10 |
IN2012DN02580A (pt) | 2015-08-28 |
EP2473055A1 (en) | 2012-07-11 |
US8779157B2 (en) | 2014-07-15 |
AU2010289281A1 (en) | 2012-04-12 |
CN102740699A (zh) | 2012-10-17 |
SG178999A1 (en) | 2012-04-27 |
IL218426A0 (en) | 2012-04-30 |
RU2012114770A (ru) | 2013-10-10 |
JP2013503909A (ja) | 2013-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012004919A2 (pt) | potencializadores alostericos de mglur4, composição e metodos de tratamentos de disfunção neurologica | |
BR112012009576A2 (pt) | potencializador alostérico de mglur4, composições, e métodos de tratamento de disfunção neurológica | |
BR112012028894A2 (pt) | sulfona heterocíclica como potenciadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica | |
HK1249446A1 (zh) | 用於治療乳糜瀉的組合物和方法 | |
HK1245098A1 (zh) | 治療慢性疼痛的方法 | |
BR112012020273A8 (pt) | compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica | |
BR112012010738A2 (pt) | ''aril e heteroaril sulfonas como potenciadores alostéricos de mglur4,composições e métodos de tratamento de disfunção neurológica'' | |
BR112012001325A2 (pt) | tratamento de distúrbios do fígado com inibidaores de pi3k | |
EP2533642A4 (en) | BENZISOXAZOLES AND AZABENZISOXAZOLES AS ALLOSTERIC POTENTIALIZERS OF METABOTROPIC GLUTAMATE RECEPTOR SUBType 4 (MGLUR4), COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS | |
BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
BR112012004979A2 (pt) | composições para o tratamento de semente e métodos | |
BR112012004149A2 (pt) | terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog | |
HUS1600057I1 (hu) | Kezelési eljárások ammónia-megkötõ hatóanyag alkalmazásával | |
BRPI0908276A2 (pt) | Métodos de tratar dor inflamatória | |
EP2361089A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE | |
BRPI1007477A2 (pt) | método, e, composição de tratamento de poço | |
BRPI0912683A2 (pt) | tratamento de tumores metastáticos | |
DK2585088T3 (da) | Sammensætning til forbedring af seksuel sundhed | |
BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
GB0909187D0 (en) | Mobility of mass selected ions | |
BRPI1009141A2 (pt) | composições e métodos para profilaxia e tratamento de vícios | |
HRP20181877T1 (hr) | Postupci za liječenje lijekovima koji uklanjaju amonijak | |
HK1244706A1 (zh) | 用於治療勃起功能障礙的組成物及方法 | |
BR112013014915A2 (pt) | composição curativa e métodos de tratamento | |
BR112012004441A2 (pt) | composição sinergística e método de uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |